INVERSAGO-PHARMA
7.9.2021 14:02:05 CEST | Business Wire | Press release
Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced that following the receipt of a No Objection Letter (NOL) from Health Canada on July 29, 2021, it has dosed the first volunteers with INV-202 in its first-in-human phase 1 clinical trial, which will evaluate the safety, tolerability and pharmacokinetics of this compound.
As a next generation peripheral CB1 inverse agonist / antagonist, INV-202 has the potential to treat various metabolic conditions such as Prader-Willi Syndrome (PWS), non-alcoholic steatohepatitis (NASH), type 1 diabetes (T1D), diabetic nephropathy and chronic kidney diseases, among others.
“Having demonstrated pharmacological characteristics that exceeded our expectations during IND-enabling preclinical studies, we’re excited to launch a second peripherally-acting CB1 blocker into the clinic with INV-202,” said Dr. Glenn Crater, MD, Chief Medical Officer of Inversago Pharma.
“With two unique, next generation CB1 blockers having entered the clinic in less than a year, we are rapidly bolstering our knowledge of this new class of drugs, which we believe may provide new treatment options for patients affected by a range of metabolic conditions,” said François Ravenelle, PhD, Chief Executive Officer of Inversago.
About INV-202
INV-202 is a small molecule CB1 inverse agonist / antagonist being developed by Inversago for the potential treatment of several metabolic conditions. It is specifically designed to preferentially interact with peripheral CB1 receptors located in the gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs, thus aiming at a safe and effective therapeutic approach without the known liabilities of centrally-acting CB1 blockers. The peripheral CB1 blockade is a well-documented pathway, linked to many clinically meaningful metabolic benefits.
About Inversago Pharma
Headquartered in Montreal, Inversago Pharma is a clinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as PWS, NASH, T1D and diabetic nephropathy. For more information, visit inversago.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005183/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International’s R2 Enters Brazil, Bringing Embedded Credit Technology to Serve SMBs and Gig Workers27.8.2026 11:00:00 CEST | Press release
R2 today announced its expansion into Brazil, marking the company's entry into Latin America's largest economy. With the support of Ant International, a leading global digital payment, digitisation and FinAI solutions provider, R2 will partner with digital platforms across Brazil to embed working capital solutions directly into the products their merchants and gig workers already use. For digital platforms, marketplaces, payment providers, ecommerce companies, and others serving SMBs and gig workers, R2 provides a proven embedded credit technology solution that enables them to offer financing to their users without building credit operations themselves, and without taking on credit risk. The result is a new revenue stream and a stronger value proposition for their merchant base. For the businesses and workers those platforms serve, it means access to working capital based on how they actually perform, not on documentation that most of them don't have. "Brazil is a defining milestone in
Samsung Display Elevates Gaming Immersion with QD-OLED at Gamescom 202627.8.2026 10:30:00 CEST | Press release
Collaborates with global game companies CAPCOM, KRAFTON and CD PROJEKT RED to showcase QD-OLED gaming experiences Offers hands-on gameplay of highly anticipated titles on about 180 QD-OLED products, highlighting QD-OLED’s fast response times, true blacks and rich color reproduction Begins mass production of 24.5-inch QD-OLED panels for eSports and first-person shooter (FPS) gaming by year-end Global PC manufacturers unveil plans to launch new products featuring Samsung Display’s 24.5-inch QD-OLED panels Samsung Display’s QD-OLED holds nearly 75% of the self-emissive monitor panel market, with lineup expansion set to further strengthen market leadership Samsung Display will showcase the gaming performance advantages of QD-OLED through collaborations with global game companies at gamescom 2026, the world’s largest gaming exhibition. The company also announced plans to begin mass production of 24.5-inch QD-OLED panels optimized for eSports and FPS games by the end of this year, underscori
SCP Standard Capital Partners AG: VANEA Defence Unveils ATOMZA®, the First Production-Ready Drone Defence System for Civilian Operators27.8.2026 08:49:00 CEST | Press release
ATOMZA® is the first counter-drone mitigation solution that can be deployed by civilian operators without sovereign enforcement powers.VANEA is opening up counter-UAS capabilities to airports, large-scale events, critical infrastructure and other sites exposed to security threats or espionage – a market previously restricted to public security authorities with the legal mandate to actively counter drones.ATOMZA is already undergoing operational testing with security authorities and critical infrastructure operators, with military trials to follow. Commercial availability for civilian operators starts immediately. VANEA Defence today unveiled ATOMZA, the world’s first drone defence system designed for civilian deployment that can be operated by private organisations without sovereign enforcement powers. The system opens up a previously inaccessible market for active counter-UAS solutions, which until now have largely been restricted to public security authorities legally authorised to i
Grid Dynamics Appoints Industry Veteran Nikita Ivanov as Head of AI26.8.2026 22:05:00 CEST | Press release
Key Takeaways: As Vice President, Head of AI, Nikita Ivanov leads the strategic direction of Grid Dynamics' AI portfolio, including its GAIN platforms, and helps clients convert AI pilots into measurable value in production. Ivanov has over two decades of founding and scaling technology companies as an entrepreneur and technologist, adding commercial and operational depth to Grid Dynamics' executive team. Focused on moving Fortune 1000 clients to AI-native software delivery, Ivanov is advancing Grid Dynamics' AI-SDLC tools that give enterprises a faster, more reliable path to building and running AI systems. Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (“Grid Dynamics”), a premier AI transformation partner for the Fortune 1000, is advancing its AI strategy under the leadership of Nikita Ivanov, Vice President, Head of AI. Ivanov is responsible for leading the transition efforts of Grid Dynamics’ clients toward an AI-native software delivery model, and he oversees all elements of Grid Dy
Arc'teryx Introduces System 0™, a New Framework for the Future of Product Design and Circularity26.8.2026 15:00:00 CEST | Press release
Sperro SV, a multisport mountain-grade hardshell built with circular design principles, available September 4, 2026 Arc'teryx Equipment, the global design company specializing in technical high-performance apparel and equipment, today introduced System 0™, a new framework that reimagines how products can be designed, manufactured, used, repaired, and ultimately regenerated. System 0 represents the next evolution for sustainability in the outdoor industry, as it embeds circular thinking across an entire product lifecycle while maintaining the uncompromising performance standards that define the Arc’teryx brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260826686539/en/ Arc’teryx athlete, Craig Murray, wearing the Sperro SV, a multisport mountain-grade hardshell built with circular design principles, available September 4, 2026. The first product being introduced as part of the System 0 platform is the Sperro SV jacket, a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom